Takotsubo Cardiomyopathy During Anti‐HER2 Therapy for Metastatic Breast Cancer

AbstractHuman epidermal growth factor receptor 2 (HER2)‐targeted antibodies, including pertuzumab and trastuzumab, improve overall survival and progression‐free survival among women with HER2‐positive metastatic breast cancer, but grade ≥3 cardiotoxicity occurs in approximately 8% of cases. Here we report a case of Takotsubo cardiomyopathy associated with the use of dual anti‐HER2 therapy in a 63‐year‐old woman who presented to the emergency department with an 8‐ to 10‐hour history of progressive dyspnea after completing her third cycle of pertuzumab plus trastuzumab in addition to nab‐paclitaxel chemotherapy. To our knowledge, this patient represents the first reported case of Takotsubo cardiomyopathy associated with pertuzumab plus trastuzumab combination therapy in the literature.

Source: The Oncologist - February 11, 2019 Category: Cancer & Oncology Authors: Caitlin Lees, Payam Yazdan-Ashoori, Katarzyna J. Jerzak, Sonal Gandhi Tags: Breast Cancer Brief Communications Source Type: research